Mirion Technologies, Inc. is a provider of radiation safety, measurement, and analysis products, software, and services. The company operates through two reporting segments: Nuclear & Safety and Medical. The Nuclear & Safety segment supplies radiation monitoring systems, reactor instrumentation, and health physics instruments for nuclear power plants, fuel cycle facilities, defense, and research laboratories. The Medical segment offers nuclear medicine instrumentation, radiation therapy equipment, diagnostic imaging quality assurance tools, and occupational dosimetry services for hospitals and cancer centers. Mirion serves customers including nuclear power operators, Small Modular Reactor developers, national laboratories, government agencies, and healthcare providers globally. The company maintains a partnership with the International Atomic Energy Agency to advance radiation detection and measurement standards. Mirion was incorporated in 2005, formed from predecessor companies active in radiation solutions since 1950.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Scientific & Technical Instruments Homepage mirion.com
Sector Technology IR page ir.mirion.com
Tags
radiation detection, nuclear power, health physics, medical imaging, radiation therapy, dosimetry services, reactor instrumentation, fuel cycle, decommissioning, defense security, Mirion Medical, Mirion Nuclear & Safety, InstadoseVUE, Certrec, Global Dosimetry Solutions
Press page ir.mirion.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 3.853B
Market cap (USD) $ 3.853B
P/E 117.67
PEG —
P/BV 2.16
P/S 3.57
P/OCF 18.38
P/FCF 22.94
Dividend yield —
Turnover / mcap —
Returns  
ROE 1.7%
ROI 1.2%
ROIC 2.0%
Profit margin 3.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 24.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 60
Quality score 17.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 925.4M 860.8M 800.9M 717.8M —
Net profit 28.8M -36.1M -96.9M -276.9M —
Free cash flow 106.9M 50.3M 58.1M 5.2M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 23.42 17.45 10.25 6.61 10.47
Price performance 12m 0.34 0.7 0.55 -0.37 —

Filed figures

Figure Jun 2019 Dec 2019 Jun 2020 Dec 2020 Jun 2021 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 97.3M — 133M 157M 171M 172M 178M 182M
↳ YoY growth +37.0% +8.8% +0.6% +3.1% +2.2%
Borrowings, current (USD) — — 41.1M — 6.4M 3.9M 5.3M 1.2M 1.2M 1.6M
Borrowings, non-current (USD) — — 670M — 886M 807M 802M 685M 685M 443M
Lease liabilities (USD) — — 0.00 — 0.00 50.8M 43.3M 35.1M 33.5M 34.5M
Cash and deposits (USD) 5,000 5,000 79,261 750M 751M 84M 73.5M 129M 175M 412M
Intangible assets (USD) — — 248M — 326M 807M 650M 539M 412M 606M
Right-of-use assets (USD) — — 0.00 — 0.00 45.7M 40.1M 32.8M 30.3M 32.1M
Net debt (borrowings + leases - cash) (USD) — — 593M — 791M 778M 777M 592M 545M 66.9M
Cash flow detail
Operating cash flow (USD) 14.7M 0.00 39.5M -945,351 53.6M — 39.4M 95.2M 99.1M 143M
Purchases of property, plant and equipment (USD) -16.5M — -19.9M — -23.2M — -34.2M -37.1M -48.8M -36.4M
Change in receivables (cash effect) (USD) 10.6M — 3.8M — -4.2M — -14.8M -5M -12M 14.6M
Change in inventories (cash effect) (USD) -7.9M — 2.7M — -4.2M — -34.8M -500,000 1.3M 3.3M
Change in payables (cash effect) (USD) -2.7M 341 -2.5M 964,734 2.6M — 4.5M -9.9M -1.5M -10.8M
Share buybacks (cash effect) (USD) — — — — 0.00 — 0.00 -1M -2M -49.6M
Interest paid (cash effect) (USD) -39.2M — -39.2M — -37.4M — -37.1M -58.5M -55.1M -37.9M
Income taxes paid (cash effect) (USD) -11.3M — -10.6M — -19.3M — -12.5M -26.3M -23.1M -27M
Share-based compensation (USD) 100,000 — 200,000 — 0.00 — 31.8M 21.9M 15.6M 15.2M
Operating cash flow before change in receivables (USD) 4.1M — 35.7M — 57.8M — 54.2M 100M 111M 129M
Free cash flow (OCF - PPE - intangibles) (USD) -1.8M — 19.6M — 30.4M — 5.2M 58.1M 50.3M 107M
Income detail
Research and development expense (USD) 14M — 15.9M — 29.4M — 30.3M 31.7M 35M 38.9M
Total comprehensive income (USD) -139M — -128M — -123M -123M -347M -87.9M -65.2M 71.5M
Comprehensive income to owners (USD) -139M — -128M — -123M -123M -332M -86.5M -63.8M 69.2M
Provision for credit losses (USD) 500,000 — 600,000 — 2.1M — 300,000 1.8M 3.4M 2.5M
Credit cost ratio (credit losses / average receivables) (%) — — — — 1.8% — 0.2% 1.0% 1.9% 1.4%
Reported Feb 28, 2022 Mar 31, 2021 Feb 28, 2022 Mar 31, 2021 Feb 28, 2024 Feb 28, 2024 Feb 28, 2024 Feb 28, 2024 Feb 26, 2025 Feb 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Sun Nuclear Debuts Simon, a Command Center for Linac Health in… Bull 2 Bear 0 Product/operations

Skip to main content

Sun Nuclear Debuts Simon, a Command Center for Linac Health in Radiation Oncology

  • Share to Facebook

  • Share to Linkedin

  • Print

November 3rd, 2026

  • Sun Nuclear announced the global launch of Simon™, a cloud-native, vendor-agnostic command center for linac health that unifies radiation therapy QA data across devices, vendors and clinical sites.

  • By turning QA data into clinical intelligence, Simon provides insights to help teams avoid machine downtime or treatment delays.

  • A Sun Nuclear-hosted webinar on November 17 will show how Simon unifies QA data and applies statistical process control to identify issues before a tolerance is breached.

Simon macbook sun nuclear pr

Melbourne, Florida – Nov. 3, 2026 – Sun Nuclear, a Mirion Medical company, announced the global launch of Simon™, a cloud-native, vendor-agnostic command center for linear accelerator (linac) health in radiation oncology. Working alongside SunCHECK® software or independently, Simon brings quality assurance (QA) data from across devices, vendors and sites into one comparable record, giving medical physicists a single view of machine health, from individual linacs to an entire network. By applying statistical process control, Simon identifies developing machine issues early, helping to avoid downtime and treatment delays.

“Quality assurance exists so that patients are treated accurately, precisely and on schedule,” said Margaret Johns, President, Sun Nuclear - Radiation Therapy QA. “Simon brings it together in one view, supporting fleet management and driving efficiency gains, while early warning helps teams avoid costly unplanned outages.”

Key benefits for radiation oncology teams include:

  • One view of the entire fleet: Shows every machine’s status in one place, including a unified calendar of QA checks, downtime, repairs and calibrations.

  • Early warning and detection: Helps teams identify drift before a tolerance trips.

  • Unified QA data: Turns results from across devices, vendors and sites into a comparable record.

  • Efficiency gains: Eliminates time spent pulling QA data into spreadsheets.

  • Standardization: Supports consistent QA across staff and sites, with visibility into whether the standard is being followed.

  • Audit readiness: Reduces effort for accreditation and audit preparation.

Early Clinical Experience at NYU Langone Health

Simon was previewed at the ASTRO 2026 Annual Meeting in Boston. David Barbee, Ph.D., DABR, Director of Technology and Innovation in Radiation at NYU Langone Health, a clinical partner in the development of Simon, spoke at the event, providing feedback after initial clinical experience with Simon. NYU Langone Health brought QA data, machine logs and Machine Performance Checks (MPC) results from its nine linacs across five regions into Simon, replacing manual processes that once took months. The team saw the early warning detection in action, discovering a jaw offset, an isocenter offset and a couch-shift alert. All three were identified while the machines were within tolerance, and they were fixed during planned maintenance.

“Standardizing our machine QA on SunCHECK across our sites in 2020 was a big step for our program. Simon is the next one,” said Barbee “With QA data, machine logs and machine performance check results together in one place, we can trend performance over time and see change earlier, turning analysis that once took months into something we can do quickly. That helps us move faster and more proactively from analysis to action, for the benefit of our patients.”

Named for an Innovator in Radiation Therapy QA

Simon is named in honor of Sun Nuclear co-founder and one of radiation therapy QA’s foremost innovators. Bill Simon, M.S., Sun Nuclear Chief Science Officer, has spent decades developing technology that helps medical physicists measure and verify radiation therapy, including innovations in detector arrays and water tank scanning, that have since evolved into the QA technology clinics and delivery system vendors rely on today. While previewing Simon at ASTRO, Luis Rivera, executive vice president of Mirion Medical, described how Bill has always let the data guide his decisions.

Sun Nuclear will host a live webinar introducing Simon on Tuesday, Nov. 17, at 11 a.m. EST. The session includes a product demonstration and an overview of how Simon works alongside SunCHECK. To register, visit the event page.

October 27, 2026 4:15 pm EDT Download as PDF

Related Documents

Earnings Webcast Audio

Presentation PDF

Infographic PDF

10-Q HTML XBRL Zip

  • Revenues for the third quarter increased 24.5% to $277.8 million, compared to $223.1 million in the same period in 2025.
  • GAAP net income was $7.8 million in the third quarter, a 151.6% increase compared to GAAP net income of $3.1 million in the same period in 2025; Adjusted EBITDA was $64.8 million in the third quarter, a 23.7% increase from $52.4 million in the same period last year.
  • GAAP net earnings per share in the third quarter was $0.03, compared to $0.01 in the same period in 2025. Adjusted earnings per share for the quarter was $0.12, compared to $0.12 in the same period in 2025. The current period calculation of Adjusted EPS includes stock based compensation expense.
  • Third quarter orders, excluding the acquisitions of Paragon and the July results of Certrec, were $340 million, a 62% increase from $209 million in the same period last year. Including the acquisitions of Paragon and the July results of Certrec, third quarter orders were $386 million, a 85% increase compared to the same period last year.
  • The company revised 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

ATLANTA--(BUSINESS WIRE)-- Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the third quarter ended September 30, 2026.

“Third quarter results showcase quarterly orders performance, an inflection in organic revenue growth, and a doubling of year-to-date adjusted free cash flow generation,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “Orders continued to trend higher, up 62% excluding acquisitions, boosted by a 105% increase in nuclear power-related orders. Organic revenue increased 6.5% in the third quarter and we expect mid-to-high teens growth in the fourth quarter. Meanwhile, adjusted free cash flow totaled $47 million in the quarter, or $107 million year-to-date. We expect to reduce net leverage to approximately 2.6x by year-end, reflecting continued strong adjusted free cash flow.”

Logan continued, “Our business is benefiting from today’s reinvestment in the existing nuclear reactor fleet. Mirion has a presence in over 98% of commercial nuclear power plants globally and approximately 80% of our nuclear power-related revenue comes from reactors operating today. Meanwhile, we continue to capture additional opportunities from large-scale new builds and small modular reactors.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “We are updating our guidance to reflect increased visibility to full year performance.”

Mirion revised 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

  • Revenue growth of approximately 24% – 25%; includes foreign exchange rate and acquisition-related impacts (previously 22.0% – 24.0%).
  • Organic Revenue growth of approximately 7% – 8% (previously 5.0% – 7.0%).
  • Adjusted EBITDA of approximately $285 million – $292 million; Adjusted EBITDA margin of approximately 24.7% – 25.2% (previously $285 million – $300 million and 25.0% - 26.0%, respectively).
  • Adjusted Free Cash Flow of approximately $170 million – $185 million; Adjusted Free Cash Flow Conversion of approximately 60% – 63% of Adjusted EBITDA (previously $155 million - $175 million and 54% - 58%, respectively).
  • Adjusted EPS of approximately $0.50 – $0.54 per share (previously $0.48 - $0.55 per share).

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free Cash Flow and Adjusted Free Cash Flow conversion are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, October 28, 2026 at 10:00 a.m. ET to discuss its financial results. A live webcast and the subsequent replay will be available at https://mirion-3q-2026.open-exchange.net . An archived replay of the call and an accompanying presentation will also be available on the Investors section of the Mirion website at https://ir.mirion.com/ .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “strive”, “seeks”, “would”, “will”, “understand” and similar words are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our backlog and order potential, our business strategy and plans, our objectives for future operations, macroeconomic trends, trends in cancer care, nuclear power and small modular reactor industries, foreign exchange, interest rate and inflation expectations and any future mergers, acquisitions, divestitures and strategic investments, including the completion and integration of previously completed transactions. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict, hostilities or geopolitical instability in the Middle East (including the U.S.-Israel-Iran conflict), tariffs, sanctions, export controls, trade restrictions or other trade and supply chain disruptions, and risks of slowing economic growth or economic recession in the United States and globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the government budget process, a U.S. government shutdown or the U.S. government’s failure to raise the debt ceiling; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets and timing of customer capital spending, procurement timing and project schedules; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or other security threats, including risks related to the implementation and enhancement of information systems and emerging technologies such as artificial intelligence; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims, litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; and the effects of health epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the United States Securities and Exchange Commission (the “SEC”) from time to time, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

In addition to our results determined in accordance with GAAP, we believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below, as well as the “Reconciliation of Non-GAAP Financial Measures” section of this press release. Non-GAAP financial information is not a substitute for GAAP financial information and undue reliance should not be placed on such non-GAAP financial information. In addition, similarly titled items used by other companies may not be comparable due to variations in how they are calculated and how terms are defined.

Channels for Disclosure of Information

Mirion intends to announce material information to the public through the Mirion Investor Relations website ir.mirion.com , SEC filings, press releases, public conference calls and public webcasts. Mirion uses these channels, as well as social media, to communicate with its investors, customers, and the public about the company, its offerings, and other issues. It is possible that the information Mirion posts on social media could be deemed to be material information. As such, Mirion encourages investors, the media, and others to follow the channels listed above, including the social media channels listed on Mirion’s investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Mirion will announce information will be posted on the investor relations page on Mirion’s website.

About Mirion

Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Nuclear & Safety group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 3,200 people and operates in 12 countries. Learn more at mirion.com .

Mirion Technologies, Inc.Condensed Consolidated Balance Sheets(Unaudited)(In millions, except share data)
September 30, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents $ 408.7 $ 412.3
Accounts receivable, net of allowance for doubtful accounts 181.7 181.6
Costs in excess of billings on uncompleted contracts 97.6 93.8
Inventories 158.7 152.6
Prepaid expenses and other current assets 58.2 53.4
Total current assets 904.9 893.7
Property, plant, and equipment, net 156.7 154.9
Operating lease right-of-use assets 38.3 32.1
Goodwill 1,859.5 1,872.4
Intangible assets, net 516.1 606.3
Other assets 25.6 28.7
Total assets $ 3,501.1 $ 3,588.1
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 67.5 $ 57.4
Deferred contract revenue 121.8 112.3
Debt, current — 1.6
Operating lease liabilities, current 7.5 7.7
Derivative liabilities, current — 20.7
Accrued expenses and other current liabilities 103.0 116.4
Total current liabilities 299.8 316.1
Debt, non-current 444.0 443.1
Convertible debt 757.6 754.5
Operating lease liabilities, non-current 33.5 26.8
Deferred income taxes, non-current 59.3 70.0
Other liabilities 70.9 60.7
Total liabilities 1,665.1 1,671.2
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit):
Class A common stock; $0.0001 par value, 500,000,000 shares authorized; 239,732,572 shares issued and outstanding at September 30, 2026; 244,662,792 shares issued and outstanding at December 31, 2025 — —
Class B common stock; $0.0001 par value, 100,000,000 shares authorized; 5,759,555 shares issued and outstanding at September 30, 2026; 5,869,555 shares issued and outstanding at December 31, 2025 — —
Treasury stock, at cost; 9,408,713 shares at September 30, 2026 and 3,492,619 shares December 31, 2025 (160.3 ) (58.4 )
Additional paid-in capital 2,511.4 2,490.1
Accumulated deficit (501.0 ) (512.7 )
Accumulated other comprehensive loss (64.2 ) (52.6 )
Mirion Technologies, Inc. stockholders’ equity 1,785.9 1,866.4
Noncontrolling interests 50.1 50.5
Total stockholders’ equity 1,836.0 1,916.9
Total liabilities and stockholders’ equity $ 3,501.1 $ 3,588.1
Mirion Technologies, Inc.Condensed Consolidated Statements of Operations(Unaudited)(In millions, except per share data)
Three Months Ended September 30, 2026 Three Months Ended September 30, 2025 Nine Months Ended September 30, 2026 Nine Months Ended September 30, 2025
Revenues:
Product $ 213.5 $ 166.1 $ 614.8 $ 478.2
Service 64.3 57.0 187.4 169.8
Total revenues 277.8 223.1 802.2 648.0
Cost of revenues:
Product 118.0 89.5 337.1 263.9
Service 28.3 29.1 81.4 81.0
Total cost of revenues 146.3 118.6 418.5 344.9
Gross profit 131.5 104.5 383.7 303.1
Operating expenses:
Selling, general and administrative 104.0 87.0 314.9 248.3
Research and development 10.3 10.1 30.0 28.8
Total operating expenses 114.3 97.1 344.9 277.1
Income from operations 17.2 7.4 38.8 26.0
Other expense (income):
Interest expense 8.4 8.9 25.2 33.2
Interest income (2.7 ) (2.2 ) (8.7 ) (6.1 )
Loss on debt extinguishment — — — 5.8
Foreign currency loss (gain), net 0.1 (0.6 ) 4.8 (16.9 )
Other expense, net 0.5 0.1 0.5 0.4
Income before income taxes 10.9 1.2 17.0 9.6
Income tax expense (benefit) 3.1 (1.9 ) 4.5 (2.4 )
Net income 7.8 3.1 12.5 12.0
Income attributable to noncontrolling interests 0.4 0.2 0.8 0.5
Net income attributable to Mirion Technologies, Inc. $ 7.4 $ 2.9 $ 11.7 $ 11.5
Earnings per common share attributable to Mirion Technologies, Inc.:
Basic $ 0.03 $ 0.01 $ 0.05 $ 0.05
Diluted $ 0.03 $ 0.01 $ 0.04 $ 0.04
Weighted average common shares outstanding:
Basic 242.390 224.583 243.864 225.084
Diluted 272.889 255.662 274.543 256.249
Mirion Technologies, Inc.Consolidated Statements of Cash Flows(Unaudited)(In millions)
Nine Months Ended September 30, 2026 Nine Months Ended September 30, 2025
OPERATING ACTIVITIES:
Net income $ 12.5 $ 12.0
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization expense 117.8 102.4
Stock-based compensation expense 18.3 11.2
Loss on debt extinguishment — 5.8
Amortization of debt issuance costs 4.2 2.8
Provision for doubtful accounts 1.0 2.0
Inventory obsolescence write down 0.8 1.5
Change in deferred income taxes (5.5 ) (9.5 )
Loss on disposal of property, plant, and equipment 0.2 0.1
Loss (gain) on foreign currency transactions 4.8 (16.9 )
Amortization of inventory step-up from purchase accounting 1.3 —
Other — 1.0
Changes in operating assets and liabilities:
Accounts receivable (3.0 ) 31.4
Costs in excess of billings on uncompleted contracts (4.9 ) (14.2 )
Inventories (13.4 ) (6.3 )
Prepaid expenses and other current assets (6.4 ) (18.8 )
Accounts payable 11.9 (10.9 )
Accrued expenses and other current liabilities (12.4 ) (10.7 )
Deferred contract revenue and liabilities 6.9 (6.7 )
Other assets 6.2 (1.5 )
Other liabilities (3.7 ) (4.4 )
Net cash provided by operating activities 136.6 70.3
INVESTING ACTIVITIES:
Purchases of property, plant, and equipment and badges (31.8 ) (26.6 )
Proceeds from net investment hedge derivative contracts 0.3 2.4
Proceeds from disposal of property, plant, and equipment and badges — 0.3
Acquisitions of businesses, net of cash and cash equivalents acquired (0.2 ) (79.9 )
Net cash used in investing activities (31.7 ) (103.8 )
FINANCING ACTIVITIES:
Stock repurchased to satisfy tax withholding for vesting restricted stock units (4.9 ) (5.2 )
Purchases of stock for treasury (96.8 ) (49.6 )
Proceeds from issuance of convertible senior notes, net of bank costs — 755.0
Third-party issuance costs — (0.9 )
Purchases of capped calls related to convertible senior notes — (82.6 )
Issuances of common stock — 425.0
Common stock issuance costs — (14.9 )
Term loan principal repayments — (244.6 )
Financing costs — (3.1 )
Proceeds from cash flow hedge derivative contracts 0.1 0.5
Other financing (0.7 ) (0.9 )
Net cash (used in) provided by financing activities (102.3 ) 778.7
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (6.2 ) 12.8
Net (decrease) increase in cash, cash equivalents, and restricted cash (3.6 ) 758.0
Cash, cash equivalents, and restricted cash at beginning of period 415.2 175.6
Cash, cash equivalents, and restricted cash at end of period $ 411.6 $ 933.6

Share Count

239,732,572 shares of Class A common stock were outstanding as of September 30, 2026. This excludes (1) 5,759,555 shares of Class B common stock outstanding as of September 30, 2026, (2) 849,354 shares of Class A common stock underlying restricted stock units, 2,044,860 shares of Class A common stock underlying performance stock units, and 2,500,000 shares of Class A common stock underlying performance stock options; and (3) any other shares issuable from future equity awards under our 2021 Omnibus Incentive Plan, which had 43,253,366 shares reserved (subject to annual automatic increases) as of September 30, 2026. The 5,759,555 shares of Class B common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for, at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is as of September 30, 2026, unless otherwise noted.

Reconciliation of Non-GAAP Financial Measures

In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Organic revenues is defined as Revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period.

Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.

Adjusted EBITDA margin is defined as Adjusted EBITDA divided by Revenue.

Adjusted net income is defined as GAAP net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense (2025 and prior), debt extinguishment and income tax impacts of these adjustments.

Adjusted EPS is defined as adjusted net income divided by weighted average common shares outstanding — basic and diluted.

Adjusted Free Cash Flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses. We believe that the inclusion of supplementary adjustments to free cash flow applied in presenting adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in acquisitions and other investing and financing activities.

Adjusted Free Cash Flow Conversion is defined as adjusted free cash flow divided by adjusted EBITDA.

Free cash flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment, purchases of badges and proceeds from derivative contracts.

Net leverage is defined as Net Debt (debt minus cash and cash equivalents) divided by Adjusted EBITDA plus contributions to Adjusted EBITDA if acquisitions made during the applicable period had been made before the start of the applicable period.

Operating Metrics

Order and orders growth are defined as the amount of revenue earned in a given period and estimated to be earned in future periods from contracts entered into in a given period as compared with such amount for a prior period. Foreign exchange rates are based on the applicable rates as reported for the time period.

The following tables present reconciliations of certain non-GAAP financial measures for the applicable periods.

Mirion Technologies, Inc.Reconciliation of Adjusted EBITDA(In millions)
Three Months Ended
September 30,
2026 2025
Income from operations $ 17.2 $ 7.4
Amortization 29.4 25.7
Depreciation 8.8 9.1
Stock-based compensation 7.1 4.4
Cost of revenues impact from inventory valuation purchase accounting (0.3 ) —
Non-operating expenses 3.1 5.4
Other expense (0.5 ) 0.4
Adjusted EBITDA $ 64.8 $ 52.4
Income from operations margin 6.2 % 3.3 %
Adjusted EBITDA margin 23.3 % 23.5 %
Mirion Technologies, Inc.Reconciliation of Adjusted Earnings per Share(In millions, except per share values)
Three Months Ended
September 30,
2026 2025
Net income attributable to Mirion Technologies, Inc. $ 7.4 $ 2.9
Income attributable to non-controlling interests 0.4 0.2
GAAP net income $ 7.8 $ 3.1
Foreign currency loss (gain), net 0.1 (0.6 )
Amortization of acquired intangibles 29.4 25.7
Stock-based compensation(1) — 4.4
Cost of revenues impact from inventory valuation purchase accounting (0.3 ) —
Non-operating expenses 3.1 5.9
Tax impact of adjustments above (8.4 ) (7.1 )
Adjusted net income $ 31.7 $ 31.4
Weighted average common shares outstanding — basic 242.390 224.583
Dilutive potential common shares - stock-based awards 0.178 0.758
Dilutive potential common shares - convertible debt 30.321 30.321
Adjusted weighted average common shares — diluted 272.889 255.662
GAAP earnings per share $ 0.03 $ 0.01
Adjusted earnings per share $ 0.12 $ 0.12
(1) The calculation for adjusted net income has been adjusted for the current period to include stock-based compensation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261027483197/en/

For investor inquiries:
Eric Linn
[email protected]

For media inquiries:
Erin Schesny
[email protected]

Source: Mirion

Released October 27, 2026

Connect With Us

Visit us on LinkedIn LinkedIn

Visit us on Youtube Youtube

©2026 Mirion Technologies, Inc. All Rights Reserved.

Skip to main content

Globe

Logo Basic Logo Wordmark Menu Close

Enter a search term

Close

Search

Chevron Close

Logo Basic

Enter a search term

Close

Search

Globe Languages and Offices Chevron

Globe Languages and Offices Chevron

  1. Home

  2. News & Press

  3. Mirion Extends Support of IAEA Mission to Advance Cancer Care Globally through Rays of Hope Donation

Mirion Extends Support of IAEA Mission to Advance Cancer Care Globally through Rays of Hope Donation

  • Share to Facebook
  • Share to Linkedin
  • Print

October 20th, 2026

  • Mirion has announced support for the IAEA Rays of Hope initiative launched by IAEA Director General Rafael Mariano Grossi in 2022 to help address disparities in access to quality cancer diagnosis and treatment in Low- and Middle-Income Countries (LMIC).
  • This milestone builds on the partnership agreement signed between Mirion and the IAEA in September 2025.
  • Sun Nuclear, a Mirion Medical company, will contribute radiation therapy quality management software, along with related quality assurance (QA) equipment and training, supporting an IAEA Anchor Centre and adjacent site in the sub-Saharan African region, as well as the IAEA Dosimetry Laboratory in Austria.

Iaea rays of hope pr

Photo credit: IAEA

ATLANTA, October 20, 2026 – Mirion, a leading provider of advanced radiation safety solutions, has announced support for the International Atomic Energy Agency (IAEA) Rays of Hope initiative, which aims to help address disparities in access to quality cancer diagnosis and treatment in Low- and Middle-Income Countries (LMIC). This milestone builds on the partnership agreement signed between Mirion and the IAEA in September 2025, which formalized Mirion’s support for the Agency’s mission to enhance radiation safety globally. The extended arrangement was signed at the opening ceremony of the IAEA International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry (IDOS), held October 5-9, in Vienna, Austria.

Under the arrangement, Mirion will contribute SunCHECK® Machine radiation therapy quality management software, along with related quality assurance (QA) equipment and training. These will be provided by Sun Nuclear, a Mirion Medical company, and a leading provider of innovative solutions for radiation therapy and diagnostic imaging. The software supports efficient, independent oversight of linear accelerators, or treatment delivery systems, through the recording, management and tracking of Machine QA data — helping clinical teams verify that equipment is performing accurately and consistently. Hardware equipment, such as Daily QA 4, supports daily, monthly and annual Machine QA. The donations will support an IAEA Anchor Centre and adjacent site in the sub-Saharan African region, as well as the IAEA Dosimetry Laboratory in Austria.

“Access to safe, high-quality radiotherapy remains uneven around the world. Rigorous quality assurance is central to closing that gap, because it gives clinical teams confidence that their treatment machines are performing as expected,” said Margaret Johns, President, Sun Nuclear - Radiation Therapy QA. “We are pleased to extend Mirion’s support of the IAEA Member States and Anchor Centres to maximize the impact of the Rays of Hope initiative, furthering our company’s commitment to advancing cancer care. We look forward to seeing the impact of Sun Nuclear’s proven software, devices and training in helping to ensure the highest quality treatment for cancer patients no matter where they live.”

“Through Rays of Hope, we are bringing together partners, expertise and resources to help expand access to life-saving cancer care to countries that need it most,” said Director General Grossi. “Partnerships with private sector play an important role in this effort, helping strengthen quality assurance, and expand access to safe and effective radiation medicine for the benefit of patients around the world.”

Before the signing ceremony, Jeff Kapatoes, Vice President, Regulatory, Physics & Product, represented Mirion in an IDOS 2026 opening ceremony segment, alongside representatives from science and private industry. He discussed Sun Nuclear’s contributions to the field of dosimetry, as well as how the organization collaborates with partners and institutions to drive advancements in the field.

To learn more about the ongoing partnership between Mirion and the IAEA, visit mirion.com .

About Mirion

Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. Focused on nuclear and safety, the Mirion Technologies group is committed to powering advancements in nuclear energy through proven radiation safety technologies and expertise. Dedicated to driving better patient outcomes, the Mirion Medical group is focused on improving quality in cancer care through its broad range of solutions that enhance the delivery and ensure safety across the medical landscape. Headquartered in Atlanta (GA – USA), Mirion employs approximately 3,200 people and operates in 12 countries. Learn more at https://www.mirion.com/ .

About Sun Nuclear

Sun Nuclear is part of Mirion Medical, a group of healthcare-focused brands within Mirion, providing innovative solutions for Radiation Therapy and Diagnostic Imaging. More than 6,000 cancer centers worldwide rely on us for independent, integrated Quality Management. With a focus on ongoing support, Sun Nuclear aims to ease technology adoption, enhance workflows and improve outcomes – so that healthcare providers can achieve real results for Patient Safety. Learn more: sunnuclear.com .

For media inquiries:
Erin Schesny
[email protected]

Related Articles

Chevron Chevron

[Mirion connect 26 emea apac logo
\

Mirion Technologies to Host Inaugural Mirion Connect EMEA/APAC Conference in Brussels\


September 28th, 2026

Mirion Technologies, a leading provider of advanced radiation safety solutions, today announced Mirion Connect 2026 EMEA/APAC, the company’s first regional edition of its Mirion Connect conference for Europe, the Middle East, Africa and Asia-Pacific region.

Mirion Technologies, a leading provider of advanced radiation safety solutions, today announced Mirion Connect 2026 EMEA/APAC, the company’s first regional edition of its Mirion Connect conference for Europe, the Middle East, Africa and Asia-Pacific region.](https://www.mirion.com/news/mirion-technologies-to-host-inaugural-mirion-connect-emea-apac-conference-in-brussels)

[Sun nuclear siemens pr
\

Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers\


September 27th, 2026

Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela.

Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela.](https://www.mirion.com/news/sun-nuclear-announces-validated-adaptive-qa-solution-in-support-of-new-radiotherapy-system-accela-by-siemens-healthineers)

[Astro press release
\

Sun Nuclear to Unveil New Innovations Aimed at Strengthening Clinical Confidence at ASTRO 2026\


September 25th, 2026

Sun Nuclear, a Mirion Medical company, will bring next-generation innovations for next-level confidence to the ASTRO 2026 Annual Meeting, beginning Sunday, September 27, in Boston.

Sun Nuclear, a Mirion Medical company, will bring next-generation innovations for next-level confidence to the ASTRO 2026 Annual Meeting, beginning Sunday, September 27, in Boston.](https://www.mirion.com/news/sun-nuclear-to-unveil-new-innovations-aimed-at-strengthening-clinical-confidence-at-astro-2026)

[Space earth moon
\

Mirion Crew Active Dosimeters to Be Worn by Astronauts on NASA’s Artemis II Mission\


March 24th, 2026

As NASA prepares for the Artemis II launch, Mirion, a leading provider of advanced radiation safety solutions, today announced that its Crew Active Dosimeters (CAD) will be carried in astronauts’ pockets aboard the Artemis II mission, providing personal, time-resolved radiation monitoring during the program’s first crewed flight.

As NASA prepares for the Artemis II launch, Mirion, a leading provider of advanced radiation safety solutions, today announced that its Crew Active Dosimeters (CAD) will be carried in astronauts’ pockets aboard the Artemis II mission, providing personal, time-resolved radiation monitoring during the program’s first crewed flight.](https://www.mirion.com/news/mirion-crew-active-dosimeters-to-be-worn-by-astronauts-on-nasas-artemis-ii-mission)

Support

Looking for Services or Support?
We're here to help.

Support

Logo Basic

Logo Basic

© 2026 Mirion Technologies, Inc. All Rights Reserved.

Prompts

Mirion Technologies, Inc. (ticker MIR), listed in United States.

Company History

Date Change Detail
Jul 29, 2021 Renamed GS ACQUISITION HOLDINGS CORP II → MIRION TECHNOLOGIES, INC.

ETFs Holding Mirion Technologies, Inc.

ETF Weight in ETF Shares Market value As of
SCAP 2.30% 30,400 $ 458.128K Aug 31, 2026
CSMD 1.92% 581,669 $ 8.713M Jul 31, 2026
PWRD 1.67% 1,620,618 $ 24.277M Jul 31, 2026
LOPP 1.62% 14,760 $ 264.647K Jun 30, 2026
GRW 1.53% 66,296 $ 993.114K Jul 31, 2026
GTEK 1.41% 222,799 $ 3.358M Aug 31, 2026
RSMC 1.38% 591,677 $ 10.082M Nov 17, 2026
NBSM 0.88% 67,389 $ 1.016M Aug 31, 2026
CLSE short -0.44% -262,817 $ -3.961M Aug 31, 2026
MMSC 0.33% 9,829 $ 167.486K Nov 16, 2026
ALAI 0.14% 35,040 $ 628.267K Jun 30, 2026
DFAS 0.09% 1,695,523 $ 30.435M Nov 12, 2026
DFSV 0.06% 891,846 $ 16.009M Nov 12, 2026
DFUV 0.02% 190,101 $ 3.412M Nov 12, 2026
IDEF 0.02% 30,140 $ 513.586K Nov 16, 2026
DXUV 0.02% 67,144 $ 1.205M Nov 12, 2026
DFAT 0.02% 317,157 $ 5.693M Nov 12, 2026
DFAC 0.02% 834,938 $ 14.987M Nov 12, 2026
MSSM 0.02% 7,204 $ 108.564K Aug 31, 2026
DFSU 0.01% 17,392 $ 312.186K Nov 12, 2026
DFAU 0.01% 61,180 $ 1.098M Nov 12, 2026
DCOR 0.01% 201,432 $ 3.616M Nov 12, 2026
DFUS 0.01% 63,899 $ 1.147M Nov 12, 2026
EBI 0.00% 1,134 $ 17.089K Aug 31, 2026
IALT short 0.00% -327 $ -5,572.08 Nov 16, 2026